Results 171 to 180 of about 626,622 (390)

The core competencies in hospital medicine: Procedures 2025 update

Journal of Hospital Medicine, EarlyView.
Abstract This article presents an updated framework from the Society of Hospital Medicine for individual learning objectives related to key procedures in hospital medicine. Building upon the 2017 framework, these objectives have been revised to reflect evolving clinical evidence, advancements, and shifts in hospital medicine practice patterns.
Satyen Nichani, Megan E. Brooks, Christine Bryson, Nick Fitterman, Meltiady Issa, Michael Lukela, Nick Marzano, Kelly Sopko, Joseph R. Sweigart   +8 more
wiley   +1 more source

Anticoagulants in venous thromboembolism. [PDF]

, 1988
A G Fennerty, I. A. Campbell, PA Routledge   +2 more
openalex   +1 more source

Research priorities for adult hospital medicine: A survey of US hospital medicine leaders

Journal of Hospital Medicine, EarlyView.
Abstract Hospital medicine (HM), a well‐established clinical specialty, requires clarity of research priorities to identify target areas for investment in HM research infrastructure and activities. The Society of Hospital Medicine's Research Committee developed a 20‐item survey and used purposeful sampling of US hospitalist leaders to prioritize ...
Valerie G. Press, James D. Harrison, Sagar B. Dugani, Blair P. Golden, Nicolas Caravelli, Andrea Jackson‐Sagredo, Valerie M. Vaughn, Andrew McWilliams, Juliessa M. Pavon, Ashley M. Jenkins, Andrew Sumarsono, Maylyn Martinez, Micah Prochaska, Stephanie K. Mueller   +13 more
wiley   +1 more source

Prophylaxis against venous thromboembolism. [PDF]

, 1992
Jean‐François Bergmann, J M Segrestaa, C Caulin   +2 more
openalex   +1 more source

Deep Vein Thrombosis in Critically Ill Patients with COVID‐19 Pneumonia

Journal of Ultrasound in Medicine, EarlyView.
Objectives The risk of major venous thromboembolism (VTE) among patients with COVID‐19 is high but varies with disease severity. Estimate the incidence of lower extremity deep venous thrombosis (DVT) in critically ill hospitalized patients with COVID‐19, validate the Wells score for DVT diagnosis, and determine patients' prognosis.
Clévio Cezar da Fonseca, Hugo Perazzo, Sandra Wagner Cardoso, Isabel Cristina Ferreira Tavares, Maria Pia Diniz Ribeiro, Rodrigo de Carvalho Moreira, Lara Esteves Coelho, Emília Moreira Jalil, André Miguel Japiassú, Elias Pimentel Gouvêa, Estevão Portela Nunes, Hugo Boechat Andrade, Luciano Barros Gouvêa, Marcel Treptow Ferreira, Pedro Mendes Azambuja‐Rodrigues, Ronaldo Ismerio Moreira, Kim Mattos Geraldo, Lucilene Araújo de Freitas, Vinicius Velleda Pacheco, Beatriz Gilda Jegerhorn Grinsztein, Pedro Emmanuel Alvarenga Americano do Brasil   +20 more
wiley   +1 more source

Diagnosis dan Tatalaksana Tromboemboli pada Kehamilan

Qanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, 2017
Venous thromboembolism is both more common and more complex to diagnose in patients who are pregnant than in those who are not pregnant. Pulmonary embolism and deep-vein thrombosis are the two components of a single disease called venous thromboembolism.
Muhammad Perdana Airlangga
doaj  

Venous thromboembolism with contraceptive use in females with sickle cell traitAJOG Global Reports at a Glance

AJOG Global Reports
BACKGROUND: Sickle cell trait is the carrier state for sickle cell disease and occurs in 1 in 13 births in Black and African American families. Individuals with sickle cell trait are permitted to serve in the military.
Angela K. Phillips, PhD, APRN, Candy Wilson, PhD, APRN, FAAN, Anwar E. Ahmed, PhD, Arun Shet, MD, PhD, Margaret Bevans, PhD, RN, FAAN   +4 more
doaj   +1 more source

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son, Yves Julien Mbama Biloa, Pauline Gouttefarde, Thomas Franck, Gilles Cizeron, Mathieu Oriol, François Maccari, Elisa Cinotti, Beatrice Trombert‐Paviot, Bienvenu Bongue, Jean‐Luc Perrot   +10 more
wiley   +1 more source

The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism [PDF]

, 1997
Sam Schulman, S. Granqvist, Margareta Holmström, Anders Carlsson, Per Lindmarker, Peter Nicol, S.‐G. Eklund, Sune Nordlander, Gerd Lärfars, Barbro Leijd, Olle Linder, Enno Loogna, Hans Walter, Stanka Viering, Martin Hjorth, Jonas Boberg   +15 more
openalex   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source